Seattle Genetics, Inc. SGEN announced that the European Commission (EC) has approved to extend the current conditional marketing authorization for its lead marketed product, Adcetris. The drug is now approved in combination with CHP (cyclophosphamide, doxorubicin, prednisone) for addressing adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics’ collaborator in Europe, Takeda Pharmaceutical Company TAK, has won this nod.
The approval was based on positive data from the phase III ECHELON-2 study, which demonstrated that treatment with Adcetris plus CHP led to superior progression-free survival and overall survival compared to CHOP chemotherapy in the given patient population.
Per the company, the approval of Adcetris plus CHP for patients with previously untreated sALCL represents a significant advance for those who were previously treated with CHOP chemotherapy regimen that was often unsuccessful in leading to long-term remissions in Europe.
In March 2020, the Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on Adcetris, recommending its approval for the given indication.
Shares of Seattle Genetics have rallied 40.1% so far this year compared with the industry’s increase of 5.7%.
The FDA approved Adcetris for six different indications. The drug is also approved for several diseases in ex-U.S. markets.
Notably, Seattle Genetics has an agreement with Takeda for the development and commercialization of Adcetris. The company retains all the rights to sell Adcetris in the United States and Canada while Takeda has commercial rights to the drug in the rest of the world.
In the first quarter of 2020, Adcetris generated net sales worth $164.1 million in the United States and Canada, up 22% year over year. The drug is also being evaluated in several label expansion studies.
Meanwhile, Seattle Genetics is studying Adcetris in combination with Bristol-Myers’ BMY Opdivo for treating Hodgkin and non-Hodgkin lymphoma. Successful development of the same and its potential approval will lend a major boost to the company.
Zacks Rank & Another Key Pick
Seattle Genetics currently holds a Zacks Rank #2 (Buy). Another top-ranked stock in the healthcare sector is Moleculin Biotech Inc MBRX, which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Moleculin Biotech’s loss per share estimates have narrowed 11.1% for 2020 and 10.4% for 2021 over the past 60 days.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BristolMyers Squibb Company (BMY) : Free Stock Analysis Report
Seattle Genetics, Inc. (SGEN) : Free Stock Analysis Report
Moleculin Biotech, Inc. (MBRX) : Free Stock Analysis Report
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research